The regulation of lipid and glucose homeostasis is of central importance to human physiology. Governing this process are both extraand intracellular receptors that sense hormones and nutrients, namely fatty acids and glucose, to control behavior and nutrient homeostasis. Hepatic lipid metabolism and glucose regulation are intimately related, and lipid accumulation can lead to metabolic diseases such as steatosis and diabetes. Recently, the dietary phospholipid DLPC (PC 12:0-12:0) was shown to lower serum lipid levels and reduce blood glucose levels in diabetic mice 1 . This effect is completely dependent on LRH-1, a phospholipid-binding orphan nuclear receptor 1 . DLPC, a medium chain phosphatidylcholine, selectively activates LRH-1-mediated transcription in luciferase assays, increases the ability of LRH-1 to interact with co-activators and increases the production of LRH-1 target genes. We have shown with MS that DLPC is able to competitively displace larger phospholipids from the ligand-binding domain (LBD) of LRH-1 in vitro, whereas longer chain phospholipids such as dipalmitoylphosphatidylcholine (DPPC; PC 16:0-16:0) cannot 1 . Thus, although a range of phospholipids bind to LRH-1 (refs. 2-4), acyl chain length and head group composition dictate transcriptional activation 1 . The mechanism governing this selective activation, however, is unclear, because the binding mode of DLPC is unknown.
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LRH-1 is a member of the NR5A class of nuclear receptors regulating the expression of genes central to embryonic development, reproduction, lipid homeostasis and energy metabolism [5] [6] [7] . LRH-1 is required to maintain transcription factor Oct4 expression in undifferentiated embryonic stem cells to maintain pluripotency 8, 9 . In breast cancer, LRH-1 regulates both estrogen synthesis and estrogen receptor (ER) expression [10] [11] [12] [13] [14] [15] . This, along with direct transcriptional regulation of LRH-1 expression by ER, makes LRH-1 a crucial element in the feed-forward loop driving sustained estrogen biosynthesis and signaling in ER-positive breast cancer [10] [11] [12] [13] [14] [15] . In hepatic tissues, LRH-1 regulates genes central to lipid and bile acid homeostasis 6 .
LRH-1 interacts with co-activators presenting an LXXLL motif (where X is any amino acid) at the interaction surface within the LBD formed by an 'active' activation-function helix (AF-H) packed against helices 3 and 4 (ref. 16 ). However, LRH-1 also uses this same active surface to interact with the atypical nuclear receptors SHP and Dax-1, which generally repress LRH-1 in hepatic tissues 17, 18 . Additionally, all NR5A receptors have crystallized with the AF-H in the active orientation. This has led to the belief that LRH-1 is not optimized to interact with typical co-repressors such as SMRT and NCoR, which require displacement of the AF-H from the active oriention to bind, and the conformation of the AF-H is not altered by ligand binding 19, 20 . Indeed, recombinant LRH-1 loaded with co-purified Escherichia coli lipids is incapable of binding to SMRT, despite being specifically repressed by SMRT in a dose-dependent manner in vivo 21 .
To investigate the general mechanism of activation and phospholipid binding capacity among LRH-1 family members, we have generated structures of apo LRH-1 and LRH-1 in complex with the activating ligand DLPC. We use HDX, thermal stability and functional assays to show that the lipid-free receptor undergoes structural fluctuations, allowing it to interact with widely expressed co-repressors. We show that binding of the antidiabetic ligand DLPC is a dynamic process that alters co-regulator selectivity, and we identify a previously unknown surface that is integral for both ligand binding and receptor activation.
RESULTS

Structure of the activated LRH-1-DLPC-TIF2 NR box 3 complex
To visualize the molecular mechanism driving DLPC biology, we determined the structure of the LRH-1 LBD in complex with DLPC and a fragment of the human co-activator transcriptional intermediary factor-2 (TIF2) to a resolution of 1.8 Å (Fig. 1a and Table 1 ). Electron density within the ligand binding pocket (LBP) showed clear evidence for bound DLPC (Fig. 1b) . Electron density was considerably weaker for the distal portions of the lipid tails, indicating that the terminal two atoms on the sn-1 acyl tail and six atoms on the sn-2 acyl tail were mobile. This was in marked contrast to the larger copurified E. coli phospholipids (C16:1-C18:1), which showed fully ordered lipid tails that intertwine to fully occupy the LBP (refs. 2,3,22) and Fig. 1c) .
We hypothesized that DLPC, with ten fewer acyl chain carbons, would insert itself deeper in the LBP. Instead, the phosphoglycerol backbone of DLPC bound to LRH-1's ~1,300 Å 3 LBP in a position similar to the phosphoglycerol backbone of E. coli lipids in previously reported structures (Fig. 1c) 2, 3, 23 . The ~240 Å 3 difference in molecular volume between the LBP-occupying atoms of DLPC and the E. coli phospholipid results in additional unoccupied space in the deepest regions of the LBP, increasing the unoccupied pocket volume to ~870 Å 3 . Earlier LRH-1-E. coli phospholipid structures were unable to identify which portions of the LBP are important for coordinating receptor activation 2, 3, 22 . The binding mode of DLPC is radically different from the endogenous ligands of other classes of nuclear receptors, as the space used to coordinate ligands in nearly all other family members is left almost completely unfilled (Fig. 1d) . Instead, the most ordered regions of the bound DLPC are near the 'mouth' of the LBP (defined by loops between helices 2 and 3, 6 and 7 and 10 and the AF-H). Comparing differential lipid-LRH-1 residue contacts between the atoms of DLPC and bacterial phospholipid in PDB 1YUC 2 , reveal that DLPC maintains contacts at the mouth of the pocket and loses contacts with residues on H5, H7 and the AF-H (Supplementary Fig. 1 and Fig. 1b) . Taken together, these results suggest that a unique set of protein-ligand interactions outside of the canonical LBP and a lack of interactions in the deepest regions of the pocket govern LRH-1 transcriptional activation by DLPC. 
Tail composition drives differential receptor dynamics
The impact of these differential contacts on the conformational dynamics of LRH-1 is difficult to predict through the crystal structure alone; therefore, we used thermal unfolding and HDX coupled to MS (HDX-MS) to assess DLPC's effect on LRH-1's LBD in solution. Consistent with the observation that DLPC occupied less space and contacted fewer amino acids than E. coli phospholipids, DLPC binding decreased the ability of LRH-1 to resist thermal denaturation ( Fig. 2a) . To identify which regions of the protein were being specifically destabilized by DLPC, we used high-resolution HDX-MS to compare the E. coli phospholipid-bound receptor and the LRH-1-DLPC complex. This solution-based structure probing revealed that the β-sheet-helix 6 region and, unexpectedly, helix 10 and the AF-H were more dynamic in the DLPC complex, suggesting that differences in phospholipid acyl tail length might affect the ability of LRH-1 to interact with co-regulators (Fig. 2b) .
Generating apo LRH-1
To date, LRH-1 has only been characterized in complex with contaminating E. coli phospholipids 2, 3 . We therefore used organic solvents to denature and strip recombinantly expressed LRH-1 LBD of bound E. coli phospholipids, followed by refolding to generate apo receptor. Lipid phosphorus assays and mass spectrometry confirmed that the receptor contained only trace amounts of phospholipids ( Fig. 3a,  Supplementary Fig. 2a and ref.
2). Circular dichroism detected similar secondary structure composition, albeit with less overall secondary structure than native LRH-1 ( Fig. 3b) .
Ligand binding alters co-regulator preference
To assess the activity of apo LRH-1, we monitored the recruitment of co-activator peptides derived from SRC-1, TIF2 and PGC-1α, as well as a co-repressor peptide derived from SHP. Apo LRH-1 showed low micromolar binding affinity for SRC-1, TIF2 and SHP, and no detectable binding to the peptide derived from PGC-1α. Upon binding various E. coli lipid isoforms with acyl tails ranging from 14 to 20 carbons, the affinity for SRC-1 was not affected, the affinity for TIF2 increased by a factor of 10 and binding to SHP decreased by a factor of 12. Finally, we tested the effect of DLPC binding on co-regulator peptide selectivity. DLPC enhanced the ability of LRH-1 to recruit SRC-1 and TIF2 approximately four-fold, had no effect on PGC-1α recruitment and abolished the interaction with SHP ( Fig. 3c and Supplementary Table 1) . Our data were consistent with the observation that medium chain phospholipids are activating, whereas long chain lipids are not 1, 24 .
b-sheet-helix-6 mobility is essential for transactivation To identify mobile regions of LRH-1 that are sensitive to ligand status, we carried out a low-resolution proteolysis protection assay (Supplementary Methods) coupled to quantitative MS. By mapping the chymotrypsin proteolysis patterns in DLPC-bound receptor versus apo receptor, we were able to identify regions of the protein that were highly mobile and protease sensitive and were stabilized upon Supplementary Fig. 2b and Supplementary Table 2) . Contrary to our expectations, we found that the most mobile portion of apo LRH-1 was helix 10 and the AF-H. This observation directly refuted the idea that the AF-H of LRH-1 is rigid and insensitive to ligand status [2] [3] [4] 19 . To quantify the relative conformational mobility of the receptor in both the apo and ligand-bound states we again used high-resolution HDX-MS and showed that the β-sheet-helix-6 region was even more dynamic than the AF-H (Fig. 4a,b and Supplementary Fig. 3 ). We also noted that regions of the receptor, such as helices 9 and 10, were specifically stabilized upon lipid binding. These helices have been recently reported to be the interaction site for β-catenin, which serves as a co-activator for LRH-1 (ref. 25) . These data suggest that β-catenin co-activation of LRH-1 might be ligand regulated.
Structure of the apo LRH-1-SHP NR box 1 complex
To visualize the structural perturbations introduced in the absence of ligand, we determined a structure of apo LRH-1, stabilized by a fragment of the atypical co-repressor SHP to a resolution of 1.9 Å, representing an inactivated form of the receptor, to juxtapose with the active LRH-1-DLPC complex ( Fig. 4c and Table 1 ). Unexpectedly, we found that in the absence of phospholipid, residues 397-421 were completely disordered, including both β-strands and helix 6, which form one wall of the LBP and one half of the mouth of the receptor (Fig. 4c,d and Supplementary Fig. 4 ). Because this region forms extensive contacts with DLPC and was identified as having an altered HDX profile when in complex with phospholipids of different length, we hypothesized that this mobile element might be important for sensing and transmitting ligand status.
To test whether conformational flexibility in this region was required for efficient phospholipid binding and transcriptional activation, we individually mutated two conserved flanking glycine residues at positions 398 and 421 to alanine (Fig. 4c) . In support of our hypothesis, we found that both mutations significantly lessened the ability of LRH-1 to activate transcription (Fig. 3d) . Only the G421A mutation significantly lowered the ability of the protein to bind phospholipids when purified from E. coli (Fig. 3a) ; however, Gly421 participates in a backbone amide H-bond with the phospholipid phosphate. Whereas a corresponding alanine mutation should preserve this interaction on the basis of allowed backbone torsion angles, the greater conformational mobility of Gly421 clearly had an important role in the recognition of phospholipids. Thus, we have identified the β-sheet-helix-6 region as a new activation function of LRH-1, critical for sensing ligand status and for driving receptor activation.
Empty receptor binds with high affinity to SMRT
Because our data showed that the AF-H was mobile in the absence of ligand, we investigated whether apo LRH-1 was capable of binding to a traditional co-repressor such as SMRT. Contrary to studies using receptor copurified with contaminating E. coli phospholipids 21 , we found that a peptide derived from SMRT containing the co-repressor motif (LXXXIXXXI/L) bound to apo LRH-1 with a 49.6 nanomolar K d (Fig. 3c and Supplementary Table 1) . This is by far the highest affinity interaction between LRH-1 and a co-regulator-derived peptide that we have tested, supporting our hypothesis that in the absence of ligand, the AF-H is free to rotate away from helix 3 and helix 4 to allow traditional co-repressor binding. 24, 26 . The binding energy gained from contacts with the ligand is not enough to explain the high affinity; rather, ligand binding allows for additional intramolecular contacts at the mouth of the LBP between helices 2 and 3, 6 and 7 and 10 and AF-H; this ultimately supports receptor activation 24 . By contrast, it is clear from the LRH-1-DLPC structure that activating phospholipids do not facilitate equivalent direct interactions. Rather, LRH-1 relies on phospholipids to bridge these critical intramolecular interactions with intermolecular interactions to achieve receptor activation. In this way, LRH-1 has tinkered with the canonical molecular switch, adapting it to respond to diverse phospholipid ligands by using the phosphoglycerol backbone to transmit a signal from helix 6 to the AF-H, while relying on deep pocket interactions with the lipid tails to fine tune receptor dynamics and thus co-regulator specificity.
In the absence of ligand, we showed by HDX-MS that LRH-1 undergoes rapid folding-to-unfolding transitions for several crucial regions within the LBD, including the helices 2, 5, 6 and the AF-H, with the majority of amide-protein exchange occurring within 30-60 s. This unexpected structural plasticity probably confers SMRT interaction, which requires displacement of the AF-H from the active orientation in order to bind. These data are consistent with previous reports showing that SMRT is capable of repressing LRH-1 in vivo in a dose-dependent manner, and they provide the first direct evidence that LRH-1 may be sensitive to repression by direct interactions with traditional co-repressors 19, 21 . Because SMRT does not bind a LRH-1-phospholipid complex, it is likely that at least a portion of LRH-1 remains in the apo form in cells. In addition, SHP is able to bind both the apo receptor and the receptor loaded with bacterial phospholipids; however, SHP binding is completely lost upon DLPC addition. As repression of LRH-1 in the liver dictates much of LRH-1 effects on gene expression 6, 27 , the effects of DLPC in the liver may be due in part to relieved SHP and SMRT repression rather than to enhanced co-activator interaction.
Like a true agonist, DLPC simultaneously enhanced co-activator peptide recruitment and disfavored both typical and atypical corepressor peptide interaction (Fig. 3c and Supplementary Table 1) . However, the co-activators SRC-1 and TIF2 retained their ability to interact with LRH-1 in the absence of ligand, explaining its low basal activity. These results clearly show that LRH-1 undergoes profound structural changes upon ligand binding, and they definitively confirm the viability of LRH-1 as a therapeutic target for both agonist and antagonist design. Our results also suggest that dietary phospholipids may have signaling effects outside of hepatic tissues. For example, if DLPC is trafficked out of the liver, it may exacerbate the malicious role of LRH in breast cancer by selectively recruiting PGC-1α to aromatase and ER promoters, driving increased estrogen synthesis to fuel local tumor growth. Finally, these findings may facilitate the development of tissue-selective LRH-1 modulators by disclosing discrete regions of the LBP that are required for the recruitment of distinct co-regulators.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/nsmb/. Accession codes. Coordinates and structure factors of LRH-1 in its apo state bound to a fragment of human SHP box1, and LRH-1 bound to DLPC and a fragment of TIF-2, have been deposited in the Protein Data Bank under accession numbers 4DOR and 4DOS, respectively.
Note: Supplementary information is available on the Nature Structural & Molecular Biology website.
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AUtHOR COntRIBUtIOns
ONLINE METHODS
Reagents. Chemicals were purchased from Sigma, Fisher or Avanti Phospholipids. pMALCH10T was a gift from J. Tesmer (University of Texas, Austin). pLIC_MBP and pLIC_HIS were gifts from J. Sondek (University of North Carolina, Chapel Hill). The SHP promoter firefly luciferase plasmid was a gift from J. Cooney (Baylor School of Medicine, Houston). Peptides were synthesized by RS Synthesis.
Protein expression and purification. The human LRH-1 LBD (residues 291-541) was purified as described previously 2 . For the LRH-1-DLPC complex, purified LRH-1 LBD was incubated with DLPC vesicles, prepared by sonication to optical clarity, at a 1:20 (protein:lipid) molar ratio for 24 h at 22 °C. Receptor was purified away from unbound lipids by size exclusion chromatography using Superdex 200 in 60 mM NaCl, 100 mM ammonium acetate (pH 7.4). Purified protein was dialyzed against 60 mM NaCl, 100 mM ammonium acetate (pH 7.4), 1 mM DTT, 1 mM EDTA and 2 mM CHAPS and concentrated using centrifugal filters with a 10-kDa cutoff to 5-7 mg ml −1 . For apo LRH-1 crystallization, purified LRH-1 LBD (residues 291-541) was incubated with 1,2-ditetracosanoyl-sn-glycero Table 1 ). Initial phases were determined using LRH-1 PDB 1YOK 3 or 1YUC 2 as a molecular replacement search model. The structure was refined using REFMAC5 within the CCP4 suite of programs 30, 31 , and model building was carried out in COOT 32, 33 . The final model for the LRH-1-TIF2-DLPC complex contains LRH-1 residues 296-538, TIF2 residues 742-751; it shows good geometry, with 99.6%% and 0.4% of the residues in the favored and allowed regions of the Ramachandran plot, respectively, as analyzed by MolProbity 34 . The final model for the apo LRH-1-SHP complex contains LRH-1 residues 300-397 and 421-538, SHP residues 16-27; it shows good geometry, with 98.5% and 1.5% of the residues in the favored and allowed regions of the Ramachandran plot, respectively, as analyzed by MolProbity 34 .
Data collection and refinement statistics can be found in Table 1 . Coordinates and structure factors have been deposited with the Protein Data Bank under accession codes 4DOR and 4DOS.
Mass spectrometry. Samples were analyzed using electrospray mass injection-MS in the negative-ion mode to detect and identify phospholipids. Approximately 6 mg of wild-type or mutant forms of LRH-1 LBD and Ftz-F1 LBD were extracted with a 2:1 chloroform:methanol solution, diluted in 200 µl of chloromethylene and analyzed by negative ion ESI-MS on a Thermo LTQ FTMS using direct injection analysis with electrospray ionization (Thermo Finnigan). All extractions were done in duplicate. The major phospholipid species were identified by accurate mass measurements and MS-MS through collisionally induced dissociation (CID), which yields product ions characteristic of the head groups and attached fatty acids. Acquisition and analyses were conducted with the instrument's Analyst QS software.
Phospholipid quantification. Six milligrams of protein was treated by chloroformmethanol extraction according to the two-step Bligh and Dyer method 35 to isolate phospholipid as described previously 2 . Phospholipid quantification was carried out according to the improved procedures for the determination of lipid phosphorus by malachite green 36 . Briefly, lipid extracts were dried completely and digested with perchloric acid (70% v/v) at 140 °C until all color disappeared. To the cooled tubes, a solution of malachite green and ammonium molybdate was added and incubated for 20 min at room temperature. The interaction between phosphomolybdenum and malachite green was monitored at 660 nm.
Generation of apo LRH-1. Pure protein was treated by 2:1 chloroform:methanol extraction to remove bound lipids according to the Bligh & Dyer method 35 . The resulting pellet containing denatured protein was washed three times with chloroform to remove any trace lipids associated with the protein or vessel. The resulting white pellet was then dried by evaporation and resuspended in 6 M guanidinium HCl. Empty protein was then refolded by fast dilution into a buffer containing 10 mM K 2 HPO 4 , 100 mM Tris (pH 7.4), 1 mM EDTA and 500 µM cetyl trimethylammonium bromide at 4 °C. After ~20 h, protein was concentrated and purified by size exclusion chromatography to ensure a homogenous population of refolded receptors. Circular dichroism spectroscopy and thermal unfolding studies. Circular dichroism studies were carried out on a Jasco J-800 spectropolarimeter with a 1-mm cell. Proteins were dissolved at a concentration of 0.2 mg ml −1 in 20 mM Tris (pH 7.4), 0.1 M sodium chloride and 10% (v/v) glycerol. Wavelength scans were done at 25 °C from 200 to 250 nm at a rate of 50 nm min −1 . For thermal unfolding studies, ellipticity was continuously monitored at 220 nm while the temperature was raised by use of a Jasco PFD-425S temperature control unit from 25 to 80 °C at a rate of 1 °C min −1 . The α-helix:β-sheet ratio was calculated using the k2d3 server (http://www.ogic.ca/projects/k2d3/) 37 .
Hydrogen-deuterium exchange-MS. Solution-phase amide HDX was carried out with a fully automated system as described previously 38 . Briefly, 4 µl of protein was diluted to 20 µl with D 2 O-containing HDX buffer and incubated at 25 °C for 10 s, 30 s, 60 s, 900 s or 3,600 s. Following on exchange, unwanted forward or back exchange was minimized, and the protein was denatured by dilution to 50 µl with 0.1% (v/v) TFA in 5 M urea (held at 1 °C). Samples were then passed across an immobilized pepsin column (prepared in house) at 50 µl min-1 (0.1% v/v TFA, 15 °C); the resulting peptides were trapped on a C8 trap cartridge (Hypersil Gold, Thermo Fisher). Peptides were then gradient-eluted (4% (w/v) CH3CN to 40% (w/v) CH3CN, 0.3% (w/v) formic acid over 5 min, 2 °C) across a 1 mm × 50 mm C18 HPLC column (Hypersil Gold, Thermo Fisher) and electrosprayed directly into an Orbitrap mass spectrometer (LTQ Orbitrap with ETD, Thermo Fisher). Data were processed with in-house software and visualized with PyMOL (Schrödinger, LLC). To measure the difference in exchange rates, we calculated the average percentage deuterium uptake for native LRH-1 LBD following 10, 30, 60, 900 and 3,600 s of on exchange. From this value, we subtracted the average percent deuterium uptake measured for the DLPC-bound LRH-1 LBD. Positive perturbation values indicate exchange rates are faster for these regions within LRH-1-DLPC.
